RxDoctor Payments Data

Sarada Penukonda, MD

Internal Medicine · Cape Coral, FLNPI 1992887061

Payments from drug & device makers

$1,066in general payments, 2019–2025

Across 58 payments — averaging $18.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$253
  • Johnson & Johnson$144
  • AstraZeneca$87
  • Intuitive Surgical$71
  • Amgen$66
  • Lilly USA, LLC$60
  • plus $385 from 13 others

What the payments were for

  • Food & beverage$1,05599%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,066 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$341,192
Medicare patients
374
Services billed
10,634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$100,201
JardianceEmpagliflozin70$96,975
OzempicSemaglutide59$85,563
XareltoRivaroxaban79$85,563
JanuviaSitagliptin Phosphate72$81,260
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$64,217
MyrbetriqMirabegron40$39,809
FarxigaDapagliflozin Propanediol18$23,224
Breo ElliptaFluticasone/Vilanterol42$22,181
JanumetSitagliptin Phos/Metformin Hcl16$20,402
LinzessLinaclotide27$14,670
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$12,733
SymbicortBudesonide/Formoterol Fumarate25$6,290
Lacosamide24$5,939
Atrovent HfaIpratropium Bromide11$4,942

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$49$101,66288 claims
GSKTrelegy Ellipta, Breo Ellipta$253$86,397108 claims
Novo NordiskOzempic$57$85,56359 claims
Johnson & JohnsonXarelto$144$85,56379 claims
AstraZenecaFarxiga, Symbicort$87$29,51443 claims
AbbVieLinzess, Synthroid$55$17,40558 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Cape Coral

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →